Business
Faron to Host Bexmarilimab Update Webcast
Faron to Host Bexmarilimab Update Webcast.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n Faron Pharmaceuticals Oy\n \n \n \n \n (\"Faron\" or \"Company\")\n \n \n \n \n \n \n \n \n \n Faron to Host Bexmarilimab Development Update Webcast on September 20, 2022\n \n \n \n \n \n \n \n \n \n Press Release, September 14, 2022 at 9:00 am EEST / 7:00 am BST / 2:00 am EDT\n \n \n \n \n \n \n \n \n \n TURKU, FINLAND\n \n / BOSTON, MA - \n Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that the Company will host a webcast to provide an update on the development of bexmarilimab, their\n wholly-owned, investigative precision immunotherapy asset. The webcast will take place on\n Tuesday, September 20 at 2:00 pm EEST, 12:00 pm BST, 7:00 am EDT.\n \n \n \n \n \n Dr. Markku Jalkanen, Chief Executive Officer of Faron will host the event. He will be joined by the following experts:\n \n \n \n \n \n ·\n Dr. Maija Hollmén, Adjunct Professor of Tumour Immunology, Group Leader and Academy Research Fellow at the MediCity Research Laboratory, Institute of Biomedicine, University of Turku, Finland\n \n \n ·\n Dr. Marie-Louise Fjällskog, Chief Medical Officer of Faron\n \n \n ·\n Dr. Jonathan Knowles, Chairman of Faron's Scientific Advisory Board\n \n \n \n \n \n \"I look forward to hosting this update webcast and, along with our invited speakers, further exploring the role we think bexmarilimab will have in the treatment of both solid tumors and hematologic malignancies,\" said Dr. Markku Jalkanen, Chief Executive Officer of Faron. \"We've significantly advanced our bexmarilimab development program in 2022 and on this webcast, will provide updates on current trials and important milestones we expect to achieve over the coming months.\"\n \n \n \n \n \n To register for the webcast on September 20, 2002, please visit:\n \n \n https://faron.videosync.fi/2022-bexmarilimab-development-update\n \n \n \n \n \n \n \n A Finnish language interview with Dr. Jalkanen covering the important information shared during the event will also take place on September 20, 2022. A link to a recording of this interview will be made available on the \"Investors\" section on Faron's web...